Decreased biochemical progression in patients with castration-resistant prostate cancer using a novel mefenamic acid anti-inflammatory therapy: A randomized controlled trial.
clinical trial
mefenamic acid
nonsteroidal anti-inflammatory drugs
prostate cancer
prostate-specific antigen
therapy
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
19
07
2019
accepted:
13
11
2019
entrez:
12
5
2020
pubmed:
12
5
2020
medline:
12
5
2020
Statut:
ppublish
Résumé
Prostate cancer (PCa) is the second most common non-dermatological cancer in men and is a growing public health problem. Castration-resistant disease (CRD) is the most advanced stage of the disease and is difficult to control. Patients with CRD may no longer accept conventional therapies as they are not in appropriate clinical conditions or they refuse to receive it. Given that inflammation is an essential component of CRD origin and progression, anti-inflammatory agents could be a therapeutic option with fenamates as one of the proposed choices. A prospective, randomized, double-blinded, 2-arm, parallel group, phase II-III clinical trial was performed involving 20 patients with CRD-PCa (with a prostate specific antigen level <100 ng/ml) that were undergoing androgen deprivation therapy (ADT) and did not accept any established treatment for that disease stage. In addition to ADT, 10 patients received placebo and 10 received mefenamic acid (500 mg orally every 12 h) for 6 months. The primary endpoint was the change in serum prostate-specific antigen (PSA) at 6 months. The PSA levels decreased significantly with mefenamic acid (an average 42% decrease), whereas there was an average 55% increase in the placebo group (P=0.024). In the patients treated with the placebo, 70% had biochemical disease progression (an increase of ≥25% in PSA levels), which did not occur in any of the patients treated with mefenamic acid (relative risk=0.12; 95% confidence interval, 0.01-0.85; P=0.033). There was a significant increase in quality of life (EQ-5D-5L score) and body mass index (BMI) with the experimental treatment. In conclusion, mefenamic acid administration decreased biochemical progression in patients with castration resistant PCa, improved their quality of life and increased their BMI. Future studies are required in order to strengthen the findings of the present clinical trial. Trial registration, Cuban Public Registry of Clinical Trials Database RPCEC00000248, August 2017.
Identifiants
pubmed: 32391109
doi: 10.3892/ol.2020.11509
pii: OL-0-0-11509
pmc: PMC7204620
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4151-4160Informations de copyright
Copyright © 2020, Spandidos Publications.
Références
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Cancer Med. 2017 Jul;6(7):1827-1836
pubmed: 28560840
Cancer. 2018 Apr 1;124(7):1326-1334
pubmed: 29338083
JAMA Oncol. 2015 Nov;1(8):1051-9
pubmed: 26270597
PLoS One. 2017 Jan 6;12(1):e0169173
pubmed: 28060948
Anticancer Res. 2019 Jul;39(7):3901-3908
pubmed: 31262919
Mol Clin Oncol. 2017 Feb;6(2):249-254
pubmed: 28357104
Cancer Causes Control. 2019 Mar;30(3):259-269
pubmed: 30701374
Braz J Med Biol Res. 2006 Jun;39(6):707-17
pubmed: 16751975
J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):789-797
pubmed: 28627024
Life Sci. 2004 Oct 1;75(20):2439-49
pubmed: 15350819
Acta Oncol. 2013 Jan;52(1):6-17
pubmed: 23020528
Palliat Med. 2017 Jan;31(1):26-34
pubmed: 27435604
Med Sci Sports Exerc. 2010 Apr;42(4):665-71
pubmed: 19952838
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
PLoS One. 2016 Apr 21;11(4):e0153413
pubmed: 27100876
Clin Cancer Res. 2016 Jan 1;22(1):9-15
pubmed: 26728408
Urology. 2007 Nov;70(5):931-5
pubmed: 18068450
Cancer Treat Rev. 2017 Apr;55:173-180
pubmed: 28411479
Semin Liver Dis. 2019 Feb;39(1):96-103
pubmed: 30634187
World J Oncol. 2019 Apr;10(2):63-89
pubmed: 31068988
BMJ. 2017 Jun 30;357:j2835
pubmed: 28667088
Lancet Oncol. 2012 May;13(5):549-58
pubmed: 22452894
Curr Treat Options Oncol. 2016 Dec;17(12):64
pubmed: 27822685
Mol Cell Endocrinol. 2006 Mar 27;248(1-2):182-91
pubmed: 16417966
Biostatistics. 2000 Mar;1(1):113-22
pubmed: 12933529
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
Oncotarget. 2017 Jul 24;8(33):55374-55383
pubmed: 28903426
Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):965-76
pubmed: 21277118
J Clin Oncol. 2018 Sep 1;36(25):2639-2646
pubmed: 30028657
Oncol Lett. 2015 Oct;10(4):2574-2578
pubmed: 26622892
Palliat Med. 2013 Apr;27(4):295-303
pubmed: 22450159
Indian J Surg Oncol. 2012 Jun;3(2):120-9
pubmed: 23730101
Prostate. 2015 Aug 1;75(11):1129-36
pubmed: 25929695
Oncogene. 2017 Aug 10;36(32):4597-4609
pubmed: 28368394
Prostate. 2010 Jun 1;70(8):883-8
pubmed: 20135645
Int J Cancer. 2017 Apr 1;140(7):1517-1527
pubmed: 28006843
Cochrane Database Syst Rev. 2017 Jul 12;7:CD012638
pubmed: 28700091
Urol Oncol. 2018 May;36(5):240.e13-240.e20
pubmed: 29454590
Endocr Relat Cancer. 2017 Apr;24(4):R145-R155
pubmed: 28209634
Curr Oncol. 2010 Sep;17 Suppl 2:S72-9
pubmed: 20882137
BMC Urol. 2016 Mar 22;16:13
pubmed: 27001073
Cold Spring Harb Perspect Med. 2018 Jun 1;8(6):
pubmed: 29101113
Scand J Public Health. 2013 Feb;41(1):58-64
pubmed: 23221377
F1000Res. 2018 Feb 28;7:246
pubmed: 29904592
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
J Pharm Pharm Sci. 2013;16(5):821-47
pubmed: 24393558
Am J Mens Health. 2018 Nov;12(6):1807-1823
pubmed: 30203706
Cancer Causes Control. 2014 Aug;25(8):933-43
pubmed: 24810654
Prostate Int. 2016 Sep;4(3):118-24
pubmed: 27689070
Expert Opin Pharmacother. 2015;16(10):1521-37
pubmed: 26067250
Prostate Cancer Prostatic Dis. 2018 Apr;21(1):147-152
pubmed: 29259292
Chin Med J (Engl). 2017 Sep 5;130(17):2082-2087
pubmed: 28836552
J Cancer. 2019 May 21;10(10):2237-2242
pubmed: 31258727
Eur J Oncol Nurs. 2009 Feb;13(1):49-59
pubmed: 19201649
Biomed Res Int. 2016;2016:3989286
pubmed: 26981530
Chem Biol Interact. 2009 Mar 16;178(1-3):138-44
pubmed: 19007764
Prostaglandins. 1986 Jun;31(6):1069-76
pubmed: 3094094
Cancer. 2008 Oct 15;113(8):2053-7
pubmed: 18780337
Cancer Nurs. 2004 Jul-Aug;27(4):314-9
pubmed: 15292727
J Natl Cancer Inst. 2016 Oct 20;109(3):
pubmed: 27754927
Int Urol Nephrol. 2012 Apr;44(2):471-7
pubmed: 21660425
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):2196-8
pubmed: 25060669
Cell Oncol (Dordr). 2014 Jun;37(3):167-78
pubmed: 24996792
Mol Pharmacol. 2005 Jan;67(1):60-8
pubmed: 15475569
Tohoku J Exp Med. 1997 Mar;181(3):361-70
pubmed: 9163851
Qual Life Res. 2018 Sep;27(9):2337-2348
pubmed: 29767329
Psychooncology. 2017 Oct;26(10):1576-1585
pubmed: 27943512
Mol Cancer Ther. 2010 Mar;9(3):617-30
pubmed: 20179163
BJU Int. 2017 May;119(5):709-716
pubmed: 27480340
Asian J Androl. 2018 May-Jun;20(3):221-229
pubmed: 29063869
Cancer Res. 2004 May 1;64(9):3334-43
pubmed: 15126378
Nat Rev Urol. 2015 May;12(5):240
pubmed: 25896180
J Chin Med Assoc. 2019 Jun;82(6):482-487
pubmed: 31180946
Jpn J Clin Oncol. 2015 Jul;45(7):688-94
pubmed: 25888709